<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613026</url>
  </required_header>
  <id_info>
    <org_study_id>AT2009</org_study_id>
    <nct_id>NCT02613026</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer</brief_title>
  <official_title>Comparative Analysis of the Efficacies of AT and AC-T Regimens in Neoadjuvant Chemotherapy of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>307 Hospital of PLA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the short-term and long-term efficacies and the
      safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide
      followed by docetaxel(AC-T group) in neoadjuvant chemotherapy of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the results of NSABP(National Surgical Adjuvant Breast and Bowel Project) B27 trial,
      anthracyclines(A) and Taxanes(T) are most commonly recommended in neoadjuvant chemotherapy of
      breast cancer.

      Pirarubicin is one of anthracyclines and by embedding the DNA double stranded, which inhibits
      DNA replication and RNA synthesis, thereby impedes the rapid growth of cancer cells.

      Docetaxel in one of taxanes and by strengthening the tubulin polymerization, inhibiting of
      microtubule depolymerization and leading to the formation of stable non functional
      microtubule bundles, which destroys mitosis of tumor cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of changes in hormone receptors status after treatment</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relative prognostic factors which influence pCR</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Combined therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirarubicin</intervention_name>
    <arm_group_label>Combined therapy group</arm_group_label>
    <arm_group_label>Sequential therapy group</arm_group_label>
    <other_name>Tetrahydropyranyl Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Combined therapy group</arm_group_label>
    <arm_group_label>Sequential therapy group</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Sequential therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histopathologically diagnosed with stage I-III breast cancers;

          -  clearly confirmed ER, PR and HER2 statuses;

          -  the state of axillary lymph nodes was determined through the relevant examination
             steps (puncture or sentinel lymph node biopsy);

               -  the patients were not treated with neoadjuvant therapy and surgery.

        Exclusion Criteria:

          -  the patients whose breasts or axillary lumps had received excision biopsy;

               -  the patients who had severely abnormal organ functions or who could not tolerate
                  chemotherapy,

               -  the patients with severe concomitant diseases;

               -  the patients with heart disease or left ventricular ejection fraction (LVEF)
                  &lt;50%.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shikai Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>307 Hospital of PLA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The fourth hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006 Apr 20;24(12):1940-9. Erratum in: J Clin Oncol. 2006 Jul 1;24(19):3221.</citation>
    <PMID>16622270</PMID>
  </reference>
  <reference>
    <citation>Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14.</citation>
    <PMID>14559892</PMID>
  </reference>
  <reference>
    <citation>Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005 Apr 20;23(12):2694-702. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808. Sovan, Atilla [corrected to Soran, Atilla].</citation>
    <PMID>15837984</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>November 22, 2015</last_update_submitted>
  <last_update_submitted_qc>November 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>307 Hospital of PLA</investigator_affiliation>
    <investigator_full_name>Shikai Wu</investigator_full_name>
    <investigator_title>Chief Physician,Department of Radiotherapy</investigator_title>
  </responsible_party>
  <keyword>Breast tumor</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Pathological complete remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

